SV2 PET Imaging With [11C]APP311

Study acronym: SV2
StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Site details revised
    • Eligibility criteria expanded, about 4 words
  2. Enrollment target: 120 to 250v15
  3. Site contact updated
    • Collaborators expanded, about 6 words
    v14
  4. Primary and study completion dates: Dec 2025 to Dec 2026
    • Interventions: [11C]APP311 (Radiation) to [11C]APP311 (Drug)
    • Site contact updated
    • Collaborators shortened, about 6 words
    v13
  5. Re-verified, no change to tracked fieldsv12
Show 10 earlier versionsHide 10 earlier versions
  1. Primary and study completion dates: Dec 2023 to Dec 2025
    • Secondary endpoints: details revised at 1 of 1 entry
    v11
  2. Re-verified, no change to tracked fieldsv10
  3. Study completion date: Dec 2025 to Dec 2023
    • Collaborators expanded, about 6 words
    v9
  4. Re-verified, no change to tracked fieldsv8
  5. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v7
  6. 2 versions Re-verified since Aug 3, 2020, no change to tracked fieldsv5-v6
  7. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  8. Re-verified, no change to tracked fieldsv3
  9. Secondary endpoint revisedv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Yale University
490 trials monitored
See 31 trials at risk
Schizophrenia
721 trials monitored
See 35 trials at risk
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
Trial Details
NCT Number NCT03995121
Lead Sponsor Yale University
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions
(from sponsor)		 Schizophrenia and Other Psychotic Disorders, Cannabis Use Disorder, Healthy
Related terms Schizophrenia
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov